Virtu Financial LLC purchased a new position in AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,050 shares of the company's stock, valued at approximately $149,000.

A number of other hedge funds have also recently made changes to their positions in ABCL. State Street Corp grew its holdings in shares of AbCellera Biologics by 1,087.3% during the second quarter. State Street Corp now owns 3,194,309 shares of the company's stock valued at $34,019,000 after buying an additional 2,925,279 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of AbCellera Biologics by 997.1% during the first quarter. Lazard Asset Management LLC now owns 3,189,837 shares of the company's stock valued at $31,100,000 after buying an additional 2,899,091 shares during the last quarter. Baillie Gifford & Co. grew its holdings in shares of AbCellera Biologics by 20.9% during the second quarter. Baillie Gifford & Co. now owns 13,354,715 shares of the company's stock valued at $142,227,000 after buying an additional 2,305,950 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of AbCellera Biologics by 385.5% during the first quarter. Renaissance Technologies LLC now owns 2,617,603 shares of the company's stock valued at $25,522,000 after buying an additional 2,078,400 shares during the last quarter. Finally, Northern Trust Corp bought a new position in shares of AbCellera Biologics during the second quarter valued at about $15,117,000. 42.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AbCellera Biologics

In other news, major shareholder Holdings Ltd. Thermopylae bought 85,102 shares of AbCellera Biologics stock in a transaction that occurred on Friday, December 16th. The shares were acquired at an average price of $10.10 per share, with a total value of $859,530.20. Following the completion of the purchase, the insider now directly owns 55,859,493 shares in the company, valued at $564,180,879.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 30.30% of the stock is currently owned by insiders.

AbCellera Biologics Trading Up 0.5 %

AbCellera Biologics (NASDAQ:ABCL – Get Rating) last issued its quarterly earnings results on Tuesday, November 8th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). The company had revenue of $101.38 million during the quarter, compared to the consensus estimate of $77.19 million. AbCellera Biologics had a return on equity of 21.15% and a net margin of 41.17%. On average, equities analysts forecast that AbCellera Biologics Inc. will post 0.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on ABCL shares. SVB Leerink dropped their price target on shares of AbCellera Biologics from $20.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, January 6th. Piper Sandler lowered their price objective on shares of AbCellera Biologics from $22.00 to $21.00 in a research report on Tuesday, November 1st. The Goldman Sachs Group assumed coverage on shares of AbCellera Biologics in a research report on Thursday, December 15th. They issued a "buy" rating and a $30.00 price target on the stock. Finally, Truist Financial assumed coverage on shares of AbCellera Biologics in a research report on Wednesday, November 16th. They issued a "buy" rating and a $29.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $28.67.

About AbCellera Biologics

(Get Rating)

AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.

Read More

• Get a free copy of the StockNews.com research report on AbCellera Biologics (ABCL)
• Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
• The Bottom Is In For Cloudflare Stock
• 3 Tickers Leading a Meme Stock Revival
• Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
• Wall Street Says These 3 Stocks Will Grow Earnings In 2023

Want to see what other hedge funds are holding ABCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating).

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.